サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439236

心臓ポンプ装置 - 世界市場の考察、競合情勢、市場予測（2030年）

Heart Pump Device - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
心臓ポンプ装置 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓ポンプ装置の市場規模は、2023年に27億3,000万米ドル、2030年までに63億5,000万米ドルに達し、2024年～2030年の予測期間にCAGRで15.16％の成長が見込まれます。心臓ポンプ装置の需要は、主に心血管疾患（CVD）の有病率の増加、老年人口の増加、パイプライン段階にある製品を持つさまざまな企業によって促進されています。心臓ポンプ装置はCOVID-19の心不全症例で非常に有益であることが判明し、パンデミック状況下でこれらの装置の需要をさらに押し上げました。心臓サプライヤーが不足しているため、心臓ポンプは世界市場の拡大を促す最適なソリューションとなっています。それにもかかわらず、ポンプの高いコストや発展途上国市場における低返済シナリオといった要因が、市場の成長を抑制すると予測されています。

心臓ポンプ装置の市場力学

米国心臓協会（American Heart Association）（2022）によると、2020年に世界で約2億4,410万人が冠動脈（虚血）性心疾患を患っています。

British Heart Foundation（2022）が提供したデータによると、2019年に全世界で約5億5,000万人、つまり14人に1人が心臓および循環器の疾患とともに生活しており、これには約2億9,000万人の女性と約2億6,000万人の男性が含まれます。

上記の資料はさらに、冠動脈（虚血性）心疾患、末梢動脈（血管）疾患、脳卒中、心房細動が2019年に世界でもっとも一般的で有病率の高い心血管疾患であると述べています。

全米保健機関（PAHO）（2022）によると、心血管疾患は他のどの疾患よりも年間死亡者数が多いです。心臓病と脳卒中に関連する死亡は、2021年の低中所得国における死亡全体の4分の3超を占めています。

心臓ポンプ装置に関する研究開発活動の増加は、心臓ポンプ装置市場の成長をさらに後押しします。例えば2022年8月、AbbottはMOMENTUM 3試験から得られたデータに基づき、同社のHeartMate 3心臓ポンプが心不全患者の生存期間を少なくとも5年延長すると発表しました。

したがって、前述の要因が今後数年間、心臓ポンプ装置市場全体を押し上げると見込まれます。

しかし、ポンプの高いコストと発展途上国における低返済シナリオが、心臓ポンプ装置市場の成長抑制要因として作用する可能性があります。

心臓ポンプ装置市場のセグメント分析

心臓ポンプ装置市場の製品セグメントでは、補助人工心臓カテゴリに属する左室補助人工心臓（LVAD）が最大のシェアを占めると予測され、これは市場でもっとも急成長しているセグメントの1つです。

これは主に、LVADに関連する利点と用途に加え、技術の進歩、臓器提供者の不足、世界の心不全の有病率の増加に起因しています。

LVADは正常な血流を回復させることによる重症心不全患者の治療を目的としています。心不全患者へのLVADの移植は救命につながり、臓器移植までの時間を稼ぐことができます。

LVADは信頼性が高く、安全システムが組み込まれています。

LVADの植込み後、患者は健康状態の向上を見せ、運動やその他の日常活動に復帰/再開することができます。

LVADは重症心不全患者に中長期的な治療ソリューションを提供します。

したがって、上記のすべての要因が心臓ポンプ装置市場の成長を促進すると予測されます。

北米が心臓ポンプ装置市場全体を独占する見込みです。

予測期間に北米が心臓ポンプ装置市場全体を独占すると予測されます。これは国内における、心血管疾患（CVD）の巨大な患者人口や、製品開発や市場の発展において非常に強力な市場であること、消費者の高い認知度、地域の主要市場企業のプレゼンスなどによるものと考えられ、これらが市場成長を促進しています。

当レポートでは、世界の心臓ポンプ装置市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 心臓ポンプ装置市場レポートのイントロダクション

第2章 心臓ポンプ装置市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 心臓ポンプ装置市場の主な要因の分析

  • 心臓ポンプ装置市場の促進要因
    • 心血管疾患（CVD）の増加
    • 老年人口の増加
    • パイプライン段階にある製品を持つさまざまな企業
  • 心臓ポンプ装置市場の抑制要因と課題
    • ポンプの高いコスト
    • 発展途上国における低返済シナリオ
  • 心臓ポンプ装置市場の機会
    • 自己調整ポンプへの選好
    • 非侵襲性でコンパクトな先進の装置の開発

第5章 心臓ポンプ装置のポーターのファイブフォース分析

第6章 心臓ポンプ装置市場のレイアウト

  • 製品別
    • 補助人工心臓
    • 大動脈内バルーンポンプ
    • 完全人工心臓
  • タイプ別
    • 植込み型心臓ポンプ装置
    • 体外式心臓ポンプ装置
  • 治療法別
    • BTT
    • BTC
    • DT
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北米の心臓ポンプ装置市場（2021年～2030年）
    • 欧州の心臓ポンプ装置市場（2021年～2030年）
    • アジア太平洋の心臓ポンプ装置市場（2021年～2030年）
    • その他の地域の心臓ポンプ装置市場（2021年～2030年）

第7章 心臓ポンプ装置の企業と製品のプロファイル

  • Abbott Laboratories
  • Abiomed, Inc.
  • Teleflex Incorporated
  • SynCardia Systems, LLC
  • St. Jude Medical Inc.
  • Berlin Heart
  • CARMAT
  • CorWave SA
  • Medtronic Inc.
  • Terumo Heart, Inc.
  • Calon Cardio-Technology Ltd.
  • NovaPump GmbH
  • Fresenius Medical Care AG & Co. KGaA
  • Angiodroid srl
  • Getinge AB

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightのサービス内容

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Heart Pump Devices Market in Global (2021-2030)
  • Table 3: Heart Pump Devices Market in Global by Product (2021-2030)
  • Table 4: Heart Pump Devices Market in Global by Type (2021-2030)
  • Table 5: Heart Pump Devices Market in Global by Therapy (2021-2030)
  • Table 6: Heart Pump Devices Market in Global by End-User (2021-2030)
  • Table 7: Heart Pump Devices Market in Global by Geography (2021-2030)
  • Table 8: Heart Pump Devices Market in North America (2021-2030)
  • Table 9: Heart Pump Devices Market in the US (2021-2030)
  • Table 10: Heart Pump Devices Market in Canada (2021-2030)
  • Table 11: Heart Pump Devices Market in Mexico (2021-2030)
  • Table 12: Heart Pump Devices Market in Europe (2021-2030)
  • Table 13: Heart Pump Devices Market in France (2021-2030)
  • Table 14: Heart Pump Devices Market in Germany (2021-2030)
  • Table 15: Heart Pump Devices Market in the United Kingdom (2021-2030)
  • Table 16: Heart Pump Devices Market in Italy (2021-2030)
  • Table 17: Heart Pump Devices Market in Spain (2021-2030)
  • Table 18: Heart Pump Devices Market in Rest of Europe (2021-2030)
  • Table 19: Heart Pump Devices Market in Asia-Pacific (2021-2030)
  • Table 20: Heart Pump Devices Market in China (2021-2030)
  • Table 21: Heart Pump Devices Market in Japan (2021-2030)
  • Table 22: Heart Pump Devices Market in India (2021-2030)
  • Table 23: Heart Pump Devices Market in Australia (2021-2030)
  • Table 24: Heart Pump Devices Market in South Korea (2021-2030)
  • Table 25: Heart Pump Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 26: Heart Pump Devices Market in the Rest of the World (2021-2030)
  • Table 27: Heart Pump Devices Market in the Middle East (2021-2030)
  • Table 28: Heart Pump Devices Market in Africa (2021-2030)
  • Table 29: Heart Pump Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Heart Pump Devices Market in Global (2021-2030)
  • Figure 3: Heart Pump Devices Market in Global by Product (2021-2030)
  • Figure 4: Heart Pump Devices Market in Global by Type (2021-2030)
  • Figure 5: Heart Pump Devices Market in Global by Therapy (2021-2030)
  • Figure 6: Heart Pump Devices Market in Global by End-User (2021-2030)
  • Figure 7: Heart Pump Devices Market in Global by Geography (2021-2030)
  • Figure 8: Heart Pump Devices Market in North America (2021-2030)
  • Figure 9: Heart Pump Devices Market in the US (2021-2030)
  • Figure 10: Heart Pump Devices Market in Canada (2021-2030)
  • Figure 11: Heart Pump Devices Market in Mexico (2021-2030)
  • Figure 12: Heart Pump Devices Market in Europe (2021-2030)
  • Figure 13: Heart Pump Devices Market in France (2021-2030)
  • Figure 14: Heart Pump Devices Market in Germany (2021-2030)
  • Figure 15: Heart Pump Devices Market in the United Kingdom (2021-2030)
  • Figure 16: Heart Pump Devices Market in Italy (2021-2030)
  • Figure 17: Heart Pump Devices Market in Spain (2021-2030)
  • Figure 18: Heart Pump Devices Market in the Rest of Europe (2021-2030)
  • Figure 19: Heart Pump Devices Market in Asia-Pacific (2021-2030)
  • Figure 20: Heart Pump Devices Market in China (2021-2030)
  • Figure 21: Heart Pump Devices Market in Japan (2021-2030)
  • Figure 22: Heart Pump Devices Market in India (2021-2030)
  • Figure 23: Heart Pump Devices Market in Australia (2021-2030)
  • Figure 24: Heart Pump Devices Market in South Korea (2021-2030)
  • Figure 25: Heart Pump Devices Market in the Rest of Asia-Pacific (2021-2030)
  • Figure 26: Heart Pump Devices Market in the Rest of the World (2021-2030)
  • Figure 27: Heart Pump Devices Market in the Middle East (2021-2030)
  • Figure 28: Heart Pump Devices Market in Africa (2021-2030)
  • Figure 29: Heart Pump Devices Market in South America (2021-2030)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Market Opportunities
  • Figure 33: PORTER's Five Force Analysis
目次
Product Code: DIMDCL0022

Heart Pump Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of cardiovascular diseases (CVDs) and increasing research and development activities

The global heart pump devices market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030. The demand for heart pump devices is primarily motivated by the increase in cardiovascular disease (CVDs) prevalence, the rise in the geriatric population, and various companies with products in their pipeline phase. Heart Pump devices were found to be extremely beneficial in heart failure cases in COVID-19 which further pushed for the demand for these devices during the pandemic situation. Due to a scarcity of heart suppliers, cardiac pumps are an optimal solution that encourages Global market expansion. Factors such as the high cost of the pump and a low repayment scenario in developing countries are nevertheless projected to inhibit the growth of the market.

Heart Pump Devices Market Dynamics:

According to the American Heart Association 2022, about 244.1 million people were globally living with coronary (ischemic) heart disease in 2020.

As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.

The source mentioned above further stated that coronary (ischemic) heart disease (200 million cases), peripheral arterial (vascular) disease (110 million cases), stroke (100 million cases), and atrial fibrillation (60 million cases) remained the commonest and prevalent cardiovascular conditions worldwide in 2019.

According to Pan American Health Organization (PAHO) 2022, cardiovascular diseases cause more deaths yearly than any other disease. Heart disease and stroke-related fatalities account for more than three-quarters of all deaths in low- and middle-income nations in 2021.

The increasing number of research and development activities pertaining to heart pump devices is further going to assist in the growth of the heart pump devices market. For example, in August 2022, Abbott based upon data obtained from the MOMENTUM 3 trial announced that its HeartMate 3 heart pump extends the survival of heart failure patients by at least five years.

Therefore, the afore-said factor will propel the overall market of heart pump devices in the upcoming years.

However, the high cost of the pump and low repayment scenario in developing countries may act as a restraint in the growth of the heart pump devices market.

Heart Pump Devices Market Segment Analysis:

Heart Pump Devices by Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Percutaneous Ventricular Assist Devices (PVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Intra-Aortic Balloon Pumps, and Total Artificial Hearts), Type (Implanted Heart Pump Device and Extracorporeal Heart Pump Device), Therapy (Bridge-To-Transplant (BTT), Bridge-To-Candidacy (BTC), and Destination Therapy (DT)), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the heart pump devices market, left ventricular assist devices (LVAD) under the ventricular assist devices category are expected to hold the largest share and are one of the fastest-growing segments in this market.

It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.

LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.

LVADs are highly reliable and come with built-in safety systems.

Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.

LVADs offer intermediate to long-term treatment solutions for severe heart failure patients.

Hence, all the above-mentioned factors are expected to drive the segment growth of the heart pump devices market.

North America is expected to dominate the overall Heart Pump Devices Market:

North America is expected to dominate the overall Heart Pump Devices market during the forecast period. This can be ascribed to the presence of a large patient pool suffering from cardiovascular diseases (CVDs), the highly potent market in terms of product development and launches, high consumer awareness, and the presence of local key market players among other factors in the country, driving the market growth.

The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020.

Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.

The increasing number of product development activities in the region is further going to accelerate the growth of the heart pump devices market. For example, in August 2021, the US Food and Drug Administration granted a breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump.

Thus, due to the increase in demand for heart pump devices in the region, there will be a subsequent rise in the growth of heart pump devices regional market during the forecast period.

Heart Pump Devices Market Companies:

Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.

Recent Developmental Activities in the Heart Pump Devices Market:

In August 2021, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous Heart Pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.

In February 2021, CARMAT received FDA approval to conduct an Early Feasibility Study (EFS) of its Total Artificial Heart in the US using BlueSync technology.

In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.

Key Takeaways from the Heart Pump Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Heart Pump Devices market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the Global Heart Pump Devices Market.

Various opportunities are available for the other competitor in the Heart Pump Devices Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Heart Pump Devices market growth in the coming future?

Target Audience who can be benefited from This Heart Pump Devices Market Report Study

Heart Pump Devices providers

Research organizations and consulting companies

Heart Pump Devices-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Heart Pump Devices

Various End-users want to know more about the Heart Pump Devices Market and the latest technological developments in the Heart Pump Devices market.

Frequently Asked Questions for the Heart Pump Devices Market:

What are Heart Pump Devices?

Heart pump devices are utilized in patients that are suffering from heart issues such as a recent cardiac arrest. They carry out the normal functions of the heart by maintaining regular cardiac circulation and replacing the heart partially or completely. After receiving the blood from the heart's lower chambers, it helps transfer the blood to all the vital organs in the body.

What is the market for Global Heart Pump Devices?

Global Heart Pump Devices Market was valued at USD 2.73 billion in 2023, growing at a CAGR of 15.16% during the forecast period from 2024 to 2030, to reach USD 6.35 billion by 2030.

What are the drivers for Global Heart Pump Devices?

The major drivers driving the demand for Heart Pump Devices are the increasing prevalence of cardiovascular diseases, the rising geriatric population, and new product development by the market players.

What are the key players operating in Global Heart Pump Devices?

Some of the key market players operating in the Heart Pump Devices market include Abbott Laboratories, Abiomed, Inc., Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc. CARMAT, CorWave SA, Medtronic Inc., Terumo Heart, Inc., Calon Cardio-Technology Ltd., NovaPump GmbH, Fresenius Medical Care AG & Co. KGaA, Angiodroid srl, Getinge AB and others.

What regions have the highest share in the Heart Pump Devices market?

North America is expected to dominate the overall Heart Pump Devices market during the forecast period, 2024 to 2030. This domination is due to the growing demand for advanced technologies in Heart Pump Devices, the increasing chronic disease in the region is driving the regional growth.

Table of Contents

1. Heart Pump Devices Market Report Introduction

2. Heart Pump Devices Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Heart Pump Devices Market Key Factors Analysis

  • 4.1. Heart Pump Devices Market Drivers
    • 4.1.1. Rise in cardiovascular diseases (CVDs)
    • 4.1.2. The rise in the geriatric population
    • 4.1.3. Various companies with products in their pipeline phase
  • 4.2. Heart Pump Devices Market Restraints and Challenges
    • 4.2.1. High cost of the pump
    • 4.2.2. Low repayment scenario in developing countries
  • 4.3. Heart Pump Devices Market Opportunities
    • 4.3.1. Preference for self-regulated pumps
    • 4.3.2. Development of non-invasive, compact, and advanced devices

5. Heart Pump Devices Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. Heart Pump Devices Market Layout

  • 6.1. By Product
    • 6.1.1. Ventricular Assist Devices
      • 6.1.1.1. Left Ventricular Assist Devices (LVAD)
      • 6.1.1.2. Percutaneous Ventricular Assist Devices (PVAD)
      • 6.1.1.3. Biventricular Ventricular Assist Devices (BIVAD)
      • 6.1.1.4. Right Ventricular Assist Devices (RVAD)
    • 6.1.2. Intra-Aortic Balloon Pumps
    • 6.1.3. Total Artificial Hearts
  • 6.2. By Type
    • 6.2.1. Implanted Heart Pump Device
    • 6.2.2. Extracorporeal Heart Pump Device
  • 6.3. By Therapy
    • 6.3.1. Bridge-To-Transplant (BTT)
    • 6.3.2. Bridge-To-Candidacy (BTC)
    • 6.3.3. Destination Therapy (DT)
  • 6.4. By End-User
    • 6.4.1. Hospitals
    • 6.4.2. Ambulatory Surgical Centers
    • 6.4.3. Others
  • 6.5 By Geography
    • 6.5.1. North America Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.1.1. United States Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.1.2. Canada Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.1.3. Mexico Heart Pump Devices Market in USD million (2021-2030)
    • 6.5.2. Europe Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.1. France Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.2. Germany Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.3. United Kingdom Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.4. Italy Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.5. Spain Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe Heart Pump Devices Market in USD million (2021-2030)
    • 6.5.3. Asia-Pacific Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.1. China Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.2. Japan Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.3. India Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.4. Australia Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.5. South Korea Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.3.6. Rest of Asia-Pacific Heart Pump Devices Market in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW) Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.4.1. Middle East Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.4.2. Africa Heart Pump Devices Market in USD million (2021-2030)
      • 6.5.4.3. South America Heart Pump Devices Market in USD million (2021-2030)

7. Heart Pump Devices Company and Product Profiles

  • 7.1. Abbott Laboratories
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Abiomed, Inc.
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Teleflex Incorporated
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. SynCardia Systems, LLC
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. St. Jude Medical Inc.
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Berlin Heart
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. CARMAT
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. CorWave SA
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Medtronic Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Terumo Heart, Inc.
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Calon Cardio-Technology Ltd.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. NovaPump GmbH
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Fresenius Medical Care AG & Co. KGaA
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Angiodroid srl
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Getinge AB
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL View

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us